AbClon Inc., a prominent South Korean biotechnology company, has been making significant strides in the biotech industry since its public debut on September 18, 2017. Listed on the Korea Exchange KOSDAQ, the company has been a focal point for investors interested in the biotechnology sector. As of August 2, 2026, AbClon Inc.’s stock closed at 21,950 KRW, reflecting its current market position.
The company’s financial journey over the past year has been marked by notable fluctuations. The 52-week high reached 95,800 KRW on March 15, 2026, showcasing a period of robust investor confidence and market performance. Conversely, the 52-week low was recorded at 9,770 KRW on August 19, 2025, indicating a period of market volatility and challenges faced by the company.
AbClon Inc.’s market capitalization stands at an impressive 437,364,948,992 KRW, underscoring its substantial presence and influence within the biotechnology industry. This valuation reflects the company’s growth trajectory and its potential to continue making impactful contributions to the field.
As a key player in the biotechnology sector, AbClon Inc. remains committed to advancing its research and development initiatives. The company’s focus on innovative solutions and cutting-edge technologies positions it well to address emerging challenges and opportunities within the industry. Investors and stakeholders continue to monitor AbClon Inc.’s progress closely, anticipating further developments and achievements in the coming years.
